Astellas Pharma (OTCMKTS:ALPMY) versus Traws Pharma (NASDAQ:TRAW) Head to Head Analysis

Astellas Pharma (OTCMKTS:ALPMY) and Traws Pharma (NASDAQ:TRAW) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, valuation, earnings, analyst recommendations, risk and institutional ownership.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Astellas Pharma and Traws Pharma, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Astellas Pharma	0	3	0	1	2.50
Traws Pharma	1	4	0	0	1.80

Traws Pharma has a consensus target price of $1.00, indicating a potential upside of 165.46%. Given Traws Pharma’s higher possible upside, analysts plainly believe Traws Pharma is more favorable than Astellas Pharma.

Institutional & Insider Ownership

8.0% of Traws Pharma shares are owned by institutional investors. 7.6% of Traws Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Astellas Pharma and Traws Pharma”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Astellas Pharma	$14.21 billion	1.97	$1.83 billion	$1.31	11.82
Traws Pharma	$2.79 million	2.08	$9.17 million	($1.74)	-0.22

Astellas Pharma has higher revenue and earnings than Traws Pharma. Traws Pharma is trading at a lower price-to-earnings ratio than Astellas Pharma, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Astellas Pharma has a beta of 0.08, suggesting that its share price is 92% less volatile than the S&P 500. Comparatively, Traws Pharma has a beta of 1.52, suggesting that its share price is 52% more volatile than the S&P 500.

Profitability

This table compares Astellas Pharma and Traws Pharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Astellas Pharma	16.01%	25.79%	12.87%
Traws Pharma	N/A	-23,868.92%	-165.52%

Summary

Astellas Pharma beats Traws Pharma on 8 of the 13 factors compared between the two stocks.

About Astellas Pharma

Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants. Th company has a research collaboration with Vivtex Corporation to evaluate Vivtex’s GI-ORIS screening and formulation platform technology to support the development of novel and oral versions of a therapeutic candidate provided by Astellas; and a partnership agreement with Roche Diabetes Care Japan Co., Ltd. to develop and commercialize integrated diabetes self-management solution. The company was founded in 1923 and is headquartered in Tokyo, Japan.

About Traws Pharma

Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza. It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.